Just one week after announcing that a drug targeting Alzheimer’s has failed to generate results, Pfizer (NYSE: PFE) said that three potential cancer treatments that it was developing have been terminated during late-stage studies.

The New York-based drug development firm said on Thursday that it had stopped a lung cancer trial involving the monoclonal antibody figitumamab after outside monitors determined that the drug would not likely demonstrate any effectiveness.

Pfizer also said that two late-stage studies of Sutent, also known as sunitinib malate, did not provide meaningful help to patients with advanced breast cancer.

The failures of the three drugs comes as the company made an announcement last week that its promising Alzheimer’s drug, Dimebon, had shown no results in two separate studies. Pfizer’s Groton and New London R&D offices were involved in the development of Dimebon, although the company’s oncology research center is headquartered in California.

“Pfizer remains committed to the development program for sunitinib and is continuing to study its potential role in the treatment of other solid tumors,” the company said in a statement, including lung, liver, prostate and bladder cancer.

Sutent’s results in treating advanced-stage breast cancer were similar to those in late-stage colon cancer patients. A study of colon-cancer patients using Sutent ended last year when the drug was found to be no more effective than standard chemotherapy. Sutent has already been approved for treating advanced kidney cancer and stomach tumors.

Pfizer said that it would continue looking at figitumamab to treat prostate, breast and lung cancers.